Anlotinib for advanced medullary thyroid cancer
Treatments studied
Part of Cancer clinical trials.
This trial studies anlotinib in people with advanced or metastatic medullary thyroid cancer that has been getting worse. It aims to see how well the treatment controls the cancer and how safe it is for patients who can’t have curative surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can reliably follow study instructions
- You have advanced or metastatic medullary thyroid cancer that cannot be removed by surgery, and it has shown progression within the last 14 months
- Your scans show at least one measurable tumor spot
- Your overall health allows treatment: generally good performance status and expected survival over 3 months
- Your recent blood and organ test results must be within required ranges (blood counts, liver, and kidney function)
- You have not taken anlotinib or similar anti-angiogenesis pills like vandetanib, cabozantinib, or sunitinib before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, anlotinib and TQB2450, for people with advanced endometrial cancer that has not responded to previous chemotherapy. The goal is to see if this combination can help control the cancer.
This study tests a combination of two drugs (tislelizumab and anlotinib) as a second treatment option for people with thymoma or thymic carcinoma whose cancer has worsened after first-line therapy. It aims to see if this combination can control the tumor and improve outcomes.
This trial tests a targeted therapy pill (anlotinib) for people with advanced thyroid cancer that stopped responding to radioactive iodine. It may slow tumor growth or shrink tumors.
This trial tests a combination of two oral and infused drugs to slow or shrink advanced thyroid cancer that has stopped responding to initial treatment. It may offer a new option for people with limited choices.
This study tests whether two targeted drugs (pralsetinib and anlotinib) can help people with a certain type of advanced thyroid cancer that has a RET gene mutation. These drugs are designed to block signals that help cancer grow. The study aims to see how well these drugs work and how safe they are.
This trial tests if the drug anlotinib can safely and effectively treat recurrent craniopharyngioma, a type of brain tumor. It is for patients whose tumor has come back or grown after previous treatment.
Hear when a new Medullary Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.